Disease Landscape and Forecast Insights

Clarivate Epidemiology’s coverage of RAS comprises epidemiological estimates of key patient populations with the biomarker in the major mature pharmaceutical markets (the United States, France,…

Clarivate Epidemiology’s coverage of epidermal growth factor receptor (EGFR)-mutated tumors comprises epidemiological estimates of key patient populations with the biomarker in the major mature…

The launch of several novel therapies and multiple label expansions for premium-priced agents will fuel significant growth of the non-Hodgkin’s lymphoma (NHL) / chronic lymphocytic leukemia (CLL…

The multi-billion-dollar non-small-cell lung cancer (NSCLC) market is highly dynamic, with a plethora of approved therapies but still a high unmet need. Immune checkpoint inhibitors such as…

The figure titled “Rheumatology biosimilars Target Product Profile: attribute importance” shows the relative importance of each of the seven attributes included in the study, derived from the…

Biomarker-driven prescribing is paramount in key oncology indications. The use of biomarkers is entrenched in non-small-cell lung cancer (NSCLC), breast cancer, and colorectal cancer. Biomarker-…

Approximately 20% of Western patients with nonsquamous NSCLC present with EGFR mutations, creating a market for targeted and personalized treatments. Although the market for EGFR-mutation-positive…

Non-small-cell lung cancer (NSCLC)—the primary cause of cancer-related mortality in China—has a very dynamic pipeline that includes numerous targeted and biomarker-driven therapies. Notably,…

Immune checkpoint inhibitors continue to dominate the treatment of non-small cell lung cancer (NSCLC), and biomarker-based approaches are increasingly segmenting the space and providing new…

Key benefits and uses Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting. Drill down into physicians’ treatment sequences and understand who to position…

Clarivate Epidemiology’s coverage of ovarian cancer comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report the diagnosed events of ovarian cancer…

Non-small-cell lung cancer (NSCLC)—the leading cause of cancer-related deaths in China—has a highly dynamic drug development pipeline, including several targeted and biomarker-driven therapies…